Clinical Trials
10 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05286801 2026-05-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06957327 2026-04-28
A Study of ERAS-601 in People With Chordoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT06787664 2026-04-13
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT05041127 2026-02-19
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02989636 2026-01-06
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04416568 2025-12-17
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00496119 2025-12-16
Proton Beam Therapy for Chordoma Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting